title: Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
abstract: Therapeutic inhibition of the vascular endothelial growth factor (VEGF) signaling pathway (VSP) is increasingly employed in the contemporary treatment of many cancer types. VSP inhibitors include the anti-VEGF monoclonal antibody (bevacizumab), soluble VEGF receptors (VEGF Trap), and small molecule tyrosine kinase inhibitors (TKIs) targeting the intracellular kinase domain of VEGF receptors. These agents are associated with cardiovascular toxicities such as hypertension, thrombosis, myocardial ischemia, and left ventricular (LV) dysfunction. Data on VSP inhibitor-associated LV dysfunction are largely limited to retrospective studies. Prospective studies are needed to establish the clinical significance of VSP inhibitor-associated LV dysfunction in the general population. Pre-clinical models of VSP inhibitor-associated LV dysfunction have identified mechanisms of cardiotoxicity and may improve our understanding of the pathophysiology underlying other cardiomyopathies. This review provides an overview of LV dysfunction that can occur in patients treated with VSP inhibitors. Potential strategies for clinical detection and management of this cardiotoxicity are explored, while acknowledging that currently available data specific to VSP-inhibitor LV dysfunction are limited. Avenues for future research are suggested.
authors.affiliation: Cardio-Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: John D
authors.initials: JD
authors.lastname: Groarke
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: David
authors.initials: D
authors.lastname: Slosky
authors.forename: Susan
authors.initials: S
authors.lastname: Cheng
authors.forename: Javid
authors.initials: J
authors.lastname: Moslehi
references.citation: J Clin Oncol. 2011 Feb 20;29(6):632-8
references.pmid: 21205755
references.citation: Circulation. 2010 Jun 29;121(25):2747-54
references.pmid: 20547927
references.citation: N Engl J Med. 2013 Aug 22;369(8):722-31
references.pmid: 23964934
references.citation: JAMA. 2014 Feb 5;311(5):507-20
references.pmid: 24352797
references.citation: Br J Cancer. 2014 Feb 4;110(3):602-8
references.pmid: 24292447
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6152-9
references.pmid: 19901116
references.citation: Am Heart J. 2012 Feb;163(2):156-63
references.pmid: 22305831
references.citation: Ann Oncol. 2013 Jun;24(6):1574-9
references.pmid: 23429865
references.citation: J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90
references.pmid: 19358937
references.citation: Thyroid. 2011 Apr;21(4):451-4
references.pmid: 21385075
references.citation: Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):410-24
references.pmid: 23677704
references.citation: Circ Res. 2003 Oct 17;93(8):697-9
references.pmid: 14512440
references.citation: J Clin Oncol. 2009 May 20;27(15):2567-9; author reply 2569-70
references.pmid: 19332708
references.citation: Curr Hypertens Rep. 2011 Dec;13(6):430-5
references.pmid: 21931979
references.citation: Eur J Echocardiogr. 2006 Mar;7(2):141-6
references.pmid: 15941672
references.citation: J Am Coll Cardiol. 2013 Apr 9;61(14):1539-47
references.pmid: 23500246
references.citation: Congest Heart Fail. 2007 Jul-Aug;13(4):215-20
references.pmid: 17673874
references.citation: Leuk Lymphoma. 2013 Dec;54(12):2627-30
references.pmid: 23488610
references.citation: J Am Coll Cardiol. 2013 Jan 8;61(1):77-84
references.pmid: 23199515
references.citation: J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90
references.pmid: 23141499
references.citation: PLoS One. 2010 Jul 21;5(7):e11693
references.pmid: 20657781
references.citation: Lancet. 2013 Jan 26;381(9863):303-12
references.pmid: 23177514
references.citation: Cancer. 2008 Jun;112(11):2500-8
references.pmid: 18386829
references.citation: Clin Transl Sci. 2009 Feb;2(1):15-25
references.pmid: 20376335
references.citation: Ann Oncol. 2002 May;13(5):710-5
references.pmid: 12075738
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4462-8
references.pmid: 19652060
references.citation: Circulation. 2004 Jun 8;109(22):2749-54
references.pmid: 15148277
references.citation: J Chin Med Assoc. 2009 Jun;72(6):323-7
references.pmid: 19541568
references.citation: Pharmacotherapy. 2009 Apr;29(4):473-8
references.pmid: 19323623
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1042-9
references.pmid: 22370326
references.citation: Exp Oncol. 2008 Jun;30(2):160-2
references.pmid: 18566583
references.citation: Am J Cardiol. 2011 May 1;107(9):1375-80
references.pmid: 21371685
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5204-12
references.pmid: 18838713
references.citation: J Clin Hypertens (Greenwich). 2011 Nov;13(11):863
references.pmid: 22051434
references.citation: Oncologist. 2008 Oct;13(10):1084-96
references.pmid: 18838439
references.citation: J Am Coll Cardiol. 2007 Nov 6;50(19):1914-31
references.pmid: 17980265
references.citation: Clin Colorectal Cancer. 2011 Sep;10(3):151-6
references.pmid: 21855035
references.citation: Ann Oncol. 2009 May;20(5):807-15
references.pmid: 19150949
references.citation: Can J Physiol Pharmacol. 2013 Aug;91(8):601-7
references.pmid: 23889668
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3450-6
references.pmid: 21810682
references.citation: N Engl J Med. 2013 Nov 7;369(19):1779-81
references.pmid: 24180496
references.citation: Am J Clin Pathol. 2008 Nov;130(5):688-95
references.pmid: 18854260
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):282-7
references.pmid: 18162550
references.citation: J Clin Oncol. 2012 Oct 10;30(29):3640-7
references.pmid: 22965962
references.citation: Ann Oncol. 2008 Sep;19(9):1613-8
references.pmid: 18436521
references.citation: Lancet Oncol. 2009 Apr;10(4):391-9
references.pmid: 19341970
references.citation: Lancet. 2007 Dec 15;370(9604):2011-9
references.pmid: 18083403
references.citation: J Clin Invest. 2010 Feb;120(2):472-84
references.pmid: 20071776
references.citation: J Clin Oncol. 2011 Jun 20;29(18):e560-2
references.pmid: 21606423
references.citation: Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
references.pmid: 22744937
references.citation: Heart Fail Clin. 2011 Jul;7(3):313-21
references.pmid: 21749883
references.citation: Am J Clin Oncol. 2010 Jun;33(3):217-20
references.pmid: 19745694
references.citation: Cardiovasc Hematol Disord Drug Targets. 2006 Dec;6(4):257-66
references.pmid: 17378771
references.citation: Ann Oncol. 2009 Sep;20(9):1535-1542
references.pmid: 19474115
references.citation: Sci Transl Med. 2013 May 29;5(187):187ra69
references.pmid: 23720580
references.citation: Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):324-31
references.pmid: 24057661
references.citation: Clin Exp Med. 2007 Dec;7(4):127-34
references.pmid: 18188524
references.citation: Circulation. 2010 Sep 7;122(10):1004-16
references.pmid: 20733101
references.citation: N Engl J Med. 2011 Oct 27;365(17):1649-50
references.pmid: 22030001
references.citation: Urol Int. 2010;84(1):119-21
references.pmid: 20173383
references.citation: Circ Heart Fail. 2013 May;6(3):420-6
references.pmid: 23425978
references.citation: J Am Soc Echocardiogr. 2013 May;26(5):493-8
references.pmid: 23562088